SFI
CTMX icon

Susquehanna Fundamental Investments’s CytomX Therapeutics CTMX Stock Holding History

Susquehanna Fundamental Investments’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$66.4K Sell
54,422
-2,323
-4% -$4.62K ﹤0.01% 909
2024
Q1 		$124K Buy
+56,745
New +$105K 0.01% 645
2021
Q3 		– Sell
-39,463
Closed -$250K – 1729
2021
Q2 		$250K Buy
+39,463
New +$307K ﹤0.01% 1421

Other funds holding CTMX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Susquehanna Fundamental Investments's CTMX Position: Q2 2024 in Review

Susquehanna Fundamental Investments reduced its CytomX Therapeutics (CTMX) stake by 4.1% in Q2 2024, selling an estimated $4.62K and leaving 54,422 shares worth $66.4K. The position accounts for ﹤0.01% of the portfolio, ranked #909.

Susquehanna Fundamental Investments first reported a position in CTMX in Q2 2021 and has held it in 3 quarters since. The position peaked at $250K in Q2 2021. 74 funds tracked by Wall St. Rank hold CTMX as of Q2 2024.

  • Susquehanna Fundamental Investments held 54,422 shares of CytomX Therapeutics worth $66.4K as of Q2 2024.
  • Susquehanna Fundamental Investments sold 2,323 CytomX Therapeutics shares in Q2 2024, an estimated $4.62K.
  • CytomX Therapeutics made up ﹤0.01% of Susquehanna Fundamental Investments's portfolio in Q2 2024, its #909 holding.
  • Susquehanna Fundamental Investments first reported a position in CytomX Therapeutics in Q2 2021 and has held it in 3 quarters since.
  • Susquehanna Fundamental Investments's CytomX Therapeutics position peaked at $250K in Q2 2021.
  • 74 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2024.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2024, filed 15 Aug 2024.